The U.S. Food and Drug Administration (FDA) has cleared radiopharmaceutical firm Jubilant DraxImage's Ruby-Fill rubidium-82 generator and elution system.
The system is used with PET to evaluate regional myocardial perfusion in adults with suspected or existing coronary artery disease (CAD). It contains strontium-82, which decays to rubidium-82 (Rb-82) and is then mixed with saline to produce a personalized patient dose of Rb-82 chloride.
The company expects to begin marketing Ruby-Fill in the current quarter of its fiscal year.
